Abstract 5865
Background
The 21-gene Breast Recurrence Score® (RS) is an established genomic tool to assess recurrence risk and adjuvant chemotherapy benefit in early breast cancer. The TAILORx study redefined group boundaries of the RS in node negative women. In the 668 patients of the NSABP-B14 study that formed the validation set of the RS younger age was significantly correlated with distant recurrence and tumour size trended toward significance. High tumour grade remained an independent prognostic factor beyond the RS. In the TAILORx study these higher risk groups were under-represented.
Methods
We compared clinical prognostic parameters of women in South East London with available RS with the TAILORx trial population. Retrospective case note analysis of all identified patients between 2013 and 2018 was completed. Women with nodal involvement were excluded. Descriptive statistics were used for comparison with patient characteristics of the TAILORx study.
Results
A total of 269 tests were identified. 42 were excluded for nodal involvement or incomplete clinical data, leaving 227 patients. Differences between the populations are demonstrated for all characteristics and will be presented at the meeting.Table:
263P Patient characteristic
RS | <11 | 11-25 | >26 | ALL |
N (%) | 34 (11) | 142 (67) | 51 (22) | 227 (100) |
Median age (range) | 48 (28-75) | 49 (28-74) | 53 (38-78) | 50 (28-78) |
≤50 yr % | 56 | 56 | 41 | 52 |
Premenopausal % | 59 | 64 | 47 | 59 |
Tumour size in cm Median (IQR) Mean (SD) | 2.0 (1.7-3.0) 2.6 ± 1.5 | 2.1 (1.5-3.0) 2.6 ± 1.8 | 2.2 (1.6-3.0) 2.4 ± 1.2 | 2.1 (1.6-3.0) 2.6 ± 1.6 |
Tumour grade % Low Intermediate High | 6 74 21 | 4 63 33 | 0 24 76 | 4 56 41 |
Clinical risk % Low High High (TAILORx) | 35 65 22 | 32 68 26 | 20 80 57 | 30 70 |
Conclusions
Our patients have a higher clinical risk than the TAILORx population. They are younger and have larger, higher grade cancers. This population is under-represented in the TAILORx study which was unable to exclude benefit in the ≤ 50 subset and may thus underestimate benefit from chemotherapy in our population. The current RS reporting is biased towards an older, low-risk population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Gousis: Travel / Accommodation / Expenses: Roche. H. Kristeleit: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Advisory / Consultancy: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract